Teriflunomide and Its Mechanism of Action in Multiple Sclerosis

Treatment of multiple sclerosis (MS) is challenging: disease-modifying treatments (DMTs) must both limit unwanted immune responses associated with disease initiation and propagation (as T and B lymphocytes are critical cellular mediators in the pathophysiology of relapsing MS), and also have minimal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bar-Or, Amit, Pachner, Andrew, Menguy-Vacheron, Francoise, Kaplan, Johanne, Wiendl, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003395/
https://www.ncbi.nlm.nih.gov/pubmed/24740824
http://dx.doi.org/10.1007/s40265-014-0212-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003395/
https://www.ncbi.nlm.nih.gov/pubmed/24740824
http://dx.doi.org/10.1007/s40265-014-0212-x

Ejemplares similares